{"ticker": {"uuid": "d119c9f6-32d1-4b4a-8760-c9890ae6dc2e", "symbol": "PRLD", "name": "Prelude Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPeXpnVFFQU0tmdG5leU1UN2tiWXlwS2pLbzZBLV9NSjhwblo2ZEgtQlJma1Z6eUNFSUhHRWxRTGdaMWMzb2pIYzY4Nnd6bm5PNnF5dkVId19KX1pDbWxZTUZValBBRFJyOTRvZnA5NXAxbmJrUEFuRTBQUU1ILVJSRWliV1ZKSzhiSTJyX0J5N1BfdWpMVlhic3h3TWhUMS00aVB0ZjJldlFySlVvbURNTDlKZTJXQ1drWmJQY1hXVEQxOE9Q?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-15T12:32:44+00:00", "published_display": "15 Jul 2026 12:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Declines 7.6% as Key Support Level Comes into Play - High Reward Trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPSFduZE1NTDFfOTFvVUlfc01IaWFBR3p1LXJ6ZkNjRGtVbVc0Q25JTm1jME9PdTU5UXpYODhyd01wVXFwQnBETHNvc1lhOThxemlfc2VEeUQ1UHBTb0ZzWGQxWDNSMmZIYkdzeTRWT1ZON05zSEtzeXl4ektyWU5ZLUstWkRtcUhJREtndGVFc3BJQUpGVzg3NnRfYVVVOFRGcndBQlVDeHFsaXBBV2xaRWdPaw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-14T01:36:17+00:00", "published_display": "14 Jul 2026 01:36", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Q1 2026 Earnings: EPS Beat by 48.7% but Stock Slides 7.6% on Pre-Revenue Status - Profit Growth Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQYVZqdE5hS3Y3TFQzaE16TkpILWlTQndhTm9FOFY2eF9rbkNhV2ZMc3J4TmNaSTVHR3JFSTRBNmNfel92cXB4Rkl0RHVTXzE2ZXNyb1ppNm9ocmt0RVQyYm9falZCVkhVb0lnWDVNbHdrcEtkZ0NVTWpyZmZJWUFZQ0d2NERPUGpsUDRyeHhXNTUxVV9YaUdodXR0N0dqWXVkVWRSVTIxcm1aQ24zWFJORy0zTUVpeklNSWdKM0xsYW0wbFlrVjgwUHdkTWtBLTB2?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-13T20:42:33+00:00", "published_display": "13 Jul 2026 20:42", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Citizens reiterates Prelude Therapeutics stock rating on IND filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOQTl5U1ZvU1BBazJuUnJSd2JTVG1SWkIwS2NEX2pGY3BOR3dTY1ZSWUJBSzVkWEpITk9BWG5KWUUzQXg4a2hGUFFTWmFJazkteXNsNTk4YldMeHlHc2xWWEJyT0dYNXZXWlNWdEhwbF9Idl9XdFl4ZndlOGhPdV9KNV96eFQxYUZoY0pEN2QyRU4xNEljeExjN0NESWNJQmFxeEZGT1ZhaEx4Y0RCSVhNUDNHX0ZIZGN3YXJHd1RvZXpTeTdhTWc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) Surges 7.4%: Breakout or Bounce? - FRAMA Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPSVpYRHd4MHJjUXNsRG1MQ0R1VUdVUGNiWkxQTk9nM3dkZ05lWnBwOWVyaks2UktnVGtNMjFHNzdLVEVrazROQm9JYXZULUNLYUNhNEU1eUYtLWVOM05hSUxsVkJDODFncUZqa3owVVp0eTFWQjdzVzFWYUp2bWV1TVBfb0J2NmdZMUZZVGxZU2toLVBCQnYtRDduVzJtMzA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2500 Growth Benchmark", "summary": "Prelude Therapeutics Incorporated (NasdaqGS:PRLD) has been added to the Russell 2500 Growth Benchmark. This news coincides with several other Russell index additions for Prelude Therapeutics on the same day, including the Russell Small Cap Comp Growth Benchmark, Russell 2000 Inde", "url": "https://www.marketscreener.com/news/prelude-therapeutics-incorporated-nasdaqgs-prld-added-to-russell-2500-growth-benchmark-ce7f5fdfdd89f423", "source_name": "marketscreener.com", "published_at": "2026-06-29T20:09:48", "published_display": "29 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 2500 Index", "summary": "Prelude Therapeutics Incorporated (NasdaqGS:PRLD) has been added to the Russell 2500 Index. This inclusion is part of a broader set of additions to various Russell indices, including the Russell Small Cap Comp Growth Benchmark, Russell 2500 Growth Benchmark, Russell 2000 Index, R", "url": "https://www.marketscreener.com/news/prelude-therapeutics-incorporated-nasdaqgs-prld-added-to-russell-2500-index-ce7f5fdfd18bf525", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:41:26", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Microcap Growth Benchmark Index", "summary": "Prelude Therapeutics Incorporated (NasdaqGS:PRLD) has been added to the Russell Microcap Growth Benchmark Index. The company is a precision oncology firm focused on developing novel cancer medicines, with a pipeline including kinases, targeted protein degraders, and degrader anti", "url": "https://www.marketscreener.com/news/prelude-therapeutics-incorporated-nasdaqgs-prld-added-to-russell-microcap-growth-benchmark-index-ce7f5fded089ff27", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:16:00", "published_display": "29 Jun 2026 08:16", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNU0o0QVFQVTdFRmJZVlU3TEF0YkpEVGxGYTNzSWVjUl9jSW9nRzYtWGR3X1owNXBWUmdaVXBmRkI1U2pFa1gwTEJZMDdrLTdMUE9RcmNUZjNVaFVka0tkZGpDajlHbTV5RE1OX3ZUZDA0ZGlnbHpLSGlYSzNCMng0ZTAtaDBBczRnaS1uU0hEdWZTZmpvZkQ0b0lVLVlfWlhWaVJlSWZmb2ppaS1xWlpBdHY3WW8xNTNhYS00ODJZUzJidXN1alY2d1FVOVUtSUlUUXRvSUVn?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2000 Dynamic Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxORW5CdlJRWW5IUzZ2NURGekg0WmtwZmlJTTlmeUpnTmZ2Qlhqb3loUE96bDNUaDk5VFBaeEw3Z0ZlcFpuVHgweGRxTS1sSUFDR0U2ejZBU1pocnZiSHI4X1NkSE1ZUzUweVg0b3hEQUgyalQ0S2lhTVQ5MmthZzVYa2hXM1NBQXlFUmc3Y2h2YXRUdldWUlY4Y2FMMjFiNUNlRS1oVDZocE1aZ0hYaUxSNWdTRndLc0VwT1RLeF82QXZlbDNTdl9tbU92aExsN0pSY0E?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 3000 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNbXVBMnR5UHY0U05JZVNkN0F6cHZhSkdlTlpETVdlZnpPNjE1eV9pYXFoMlF3amgtNl9lakM1UlBTWkNnV2FmeUdhSF9oNXRzdXJFV1l4M0NSeFZqeEZpTVRUeWFlRHItZDdJU2c1WXBVSWJmaHBNRFdwUTd4TkZra250Rm12Ymt5YUFYRFN6WmlrNmdZRXdzZEZNdDd2ZEQzMTRFcEhjX0NkcnI0bHZOOV82WGhNaFdNTGdFTHlibWhPSXpQbUJj?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Completeness Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOckNNR1p1c0dfdy1OdXdEaC1rUjlNNkM3VlVaNXRfVDBZd0VmT05hNHcyMjBvQ0RXSzZEQ1NWRFduczM3YTJva2dnUHJhYnlPZFFXUHUwampMaklYTlFEOGI4ekhXNGVuWWQ5NXk4Mlh0UmZhYjNQaDljdVNXQmFHSE92bXpJXzRoYXVqaXJ3UzNOTm9QUDhjTy1vY0dmbkVUOU5hMTEwc1JnbUFWeGFxSlZkWHZ0S0FSQlhCNGhNVld1T1JYbkgxN0d1ODE5QV82MG1aMm13QjlsaDI4RGxF?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) Slips Slightly as Traders Eye Key Support Zone - Triangle Correction", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQeTdnQjd1elk4d1dTRE5fdVBSRVg5X3pSU0liTjNtcUM1Rk42cTRzTkRBUFVfZXV2M2NRZGQ1LS0zdDYzcjhaajQtNjZPdnFTc1JVcGI5d3dCNVBaQ2lZSkVWalQ5eXQtUjZIQ052RkVmNUwtS3dEdElmVjU3OHpnWFJETkgxT05yMFhaMEpQVGJfV05jSDhIR2Y0X3ZPMHBvSW9xbW1PaHdNZV9vS1ZTbzVMWnp3LUE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes the valuation of Prelude Therapeutics Inc (PRLD), highlighting its current valuation score of 6.01, which ranks it 367 out of 389 in the Biotechnology & Medical Research industry. It notes the company's current P/E ratio of -4.34, which is significantly belo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T12:09:50", "published_display": "18 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Prelude Therapeutics Inc (PRLD), detailing its current stock price momentum, support and resistance levels, and indicator and moving average readings as of June 18, 2026. The stock is currently trading between $3.58 and $4.87, with va", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/technical", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:15", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Prelude Therapeutics Inc (PRLD), including its major individual and institutional investors. Key shareholders like OrbiMed Advisors, Baker Bros. Advisors LP, and RA Capital Management LP are highlighted, along with a breakdown of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:57:40", "published_display": "17 Jun 2026 21:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article for Prelude Therapeutics Inc (PRLD) states that relevant data regarding the company's revenue breakdown by business segment and by region have not yet been disclosed. It indicates that the company's financial information in these specific categories is currently unav", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:37", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Market Sentiment Around Loss-Making Prelude Therapeutics Incorporated (NASDAQ:PRLD)", "summary": "This article examines the market sentiment surrounding Prelude Therapeutics (NASDAQ:PRLD), a loss-making biotechnology company. It highlights that despite recent positive movements in its stock price, analysts have maintained a bearish stance with an average price target indicati", "url": "https://www.moomoo.com/news/post/71485537/market-sentiment-around-loss-making-prelude-therapeutics-incorporated-nasdaq-prld", "source_name": "Moomoo", "published_at": "2026-06-17T13:11:00", "published_display": "17 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Prelude Therapeutics Inc (PRLD) has an earnings forecast score of 8.67, ranking it 71st in the Biotechnology & Medical Research industry. Analysts project an average price target of $4.00, with an upside potential of 79.37%. Most analysts currently rate PRLD as a \"Buy.\"", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T23:09:29", "published_display": "16 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) shareholders back directors, auditor and say-on-pay", "summary": "Prelude Therapeutics shareholders approved all proposals at their 2026 Annual Meeting. They re-elected three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratified Ernst & Young LLP as the independent auditor for 2026, and gave advisory approval for 2025 e", "url": "https://www.stocktitan.net/sec-filings/PRLD/8-k-prelude-therapeutics-inc-reports-material-event-aed5b467638c.html", "source_name": "Stock Titan", "published_at": "2026-06-11T10:40:37", "published_display": "11 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) director receives 38,000 stock options at $3.94 strike", "summary": "Prelude Therapeutics director Paul A. Friedman was granted 38,000 stock options at an exercise price of $3.94 per share, expiring on June 8, 2036. These options are part of his board compensation and will vest on the earlier of the company\u2019s next annual stockholder meeting or one", "url": "https://www.stocktitan.net/sec-filings/PRLD/form-4-prelude-therapeutics-inc-insider-trading-activity-653de6cd6079.html", "source_name": "Stock Titan", "published_at": "2026-06-11T09:10:22", "published_display": "11 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options", "summary": "Prelude Therapeutics Inc. director Katina Dorton was granted 38,000 stock options with an exercise price of $3.94 per share, expiring on June 8, 2036. The options will fully vest on the earlier of the next annual stockholder meeting or the one-year anniversary of the grant date, ", "url": "https://www.stocktitan.net/sec-filings/PRLD/form-4-prelude-therapeutics-inc-insider-trading-activity-78d73cac888a.html", "source_name": "Stock Titan", "published_at": "2026-06-10T22:09:51", "published_display": "10 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Prelude Therapeutics Inc Insider Trading Activity", "summary": "Prelude Therapeutics Inc. director David P. Bonita was granted 38,000 stock options with an exercise price of $3.94 per share, expiring on June 8, 2036. The options will vest upon the company's next annual stockholder meeting or the one-year anniversary of the grant date, conting", "url": "https://www.stocktitan.net/sec-filings/PRLD/form-4-prelude-therapeutics-inc-insider-trading-activity-24bb5f4378d1.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:09:24", "published_display": "10 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) director granted 38,000 stock options at $3.94", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOY1k2dlFYQlEtaXdxenM1Y2ZQb0lZUGRDb2ZNUl91elNmUjc1b0VSTHE1Y0p4T0xhdld0RjIweTMzSHNwWEd2bWFBQjFfNkJyc1R6eUx2dFJNc3NhMjR6dXBUM1VsaXlGekNaWXdUYUM1VlJrZExwa1JfWk5idHFKMno5VFdiUkg2U1AxbWs0NHIyUUlOUUtyZFQyZzFkMjFYYzJIY3VFVnh4Y2dpQWxTYWw1aXlSV0dTQlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRLD: All director, auditor, and executive compensation proposals were approved by shareholder vote", "summary": "Shareholders of Prelude Therapeutics Incorporated (PRLD) approved all proposals at their recent annual general meeting. This included the election of three directors, ratification of the company's auditor, and approval of executive compensation and its annual review. The final re", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3531294:0-prld-all-director-auditor-and-executive-compensation-proposals-were-approved-by-shareholder-vote/", "source_name": "TradingView", "published_at": "2026-06-09T13:10:11", "published_display": "09 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNc0k4enlKM1dzYWZFQlF0eUN0QnlhVFBLbHlaSUx6QjhFUkE2NWxRaU0yOHIzTXFaeFYtSi1qaVlnSXJkY3ExWE8yUG1FWHowcTROUDJsZFNkNkhWdjNSN2E5RVBOdHVhTEpWQ1E5WUxfb2ZlVXhSYWFTMlNpb3FIaEJvQ29mTEVXNG9mdWZnWDJwMm1ydDltV0xtYmc1S1JKcVB4bUpkZHZDQzRVWEE?oc=5", "source_name": "Market source", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRLD - Prelude Therapeutics Inc Stock Price and Quote", "summary": "This page provides detailed stock information for Prelude Therapeutics Inc (PRLD), including its current stock price, financial metrics, analyst ratings history, and recent news. It lists key financial data, performance indicators, insider transactions, and a chronological news f", "url": "https://finviz.com/stock?t=PRLD", "source_name": "Finviz", "published_at": "2026-05-29T15:41:33", "published_display": "29 May 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (Nasdaq:PRLD) - Stock Analysis", "summary": "This extensive analysis of Prelude Therapeutics (PRLD) covers its stock performance, financial health, and pipeline developments. The company, a clinical-stage precision oncology firm, is currently unprofitable but forecasts strong revenue growth. Recent updates include positive ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prld/prelude-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-05-20T11:12:46", "published_display": "20 May 2026 11:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates", "summary": "Following its first-quarter results, Prelude Therapeutics (NASDAQ:PRLD) saw a dip in share price, but analysts quickly upgraded their estimates. Revenue forecasts for 2026 increased to US$27.3m, and the projected loss per share significantly narrowed to US$0.37. The company's pri", "url": "https://www.sahmcapital.com/news/content/prelude-therapeutics-incorporated-nasdaqprld-reported-earnings-last-week-and-analysts-are-already-upgrading-their-estimates-2026-05-16", "source_name": "Sahm", "published_at": "2026-05-17T10:40:45", "published_display": "17 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNkRnMTVndWlSUmxTZWh2YV9Gb3pfbFB4amluWkVtR3BkTzRWRWlNcjZXU2FZY3JtWlowMUd4M3hYaGZmZG1Xa19qVjJwdHI3QzRoclNWUW5KTDFGa2hicVprTmVGYnotTzVObTBaUUo0ZnBZWHIwZDctT09jbmxmNWo2bkdJMVFQOTZNa0NSZW04cHhySWRBNW0xdVplM2VNMVhzeF9mTFZkWmxNSlllY1J3?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech", "summary": "Goldman Sachs has initiated coverage of Prelude Therapeutics Inc. (NASDAQ:PRLD) with an \"Early-Stage Biotech\" rating. The clinical-stage company, which develops cancer medicines, has seen its stock gain 377% over the past year and possesses over $10 billion in potential unadjuste", "url": "https://www.investing.com/news/analyst-ratings/goldman-sachs-initiates-prelude-therapeutics-stock-coverage-as-earlystage-biotech-93CH-4691443", "source_name": "Investing.com", "published_at": "2026-05-15T09:40:27", "published_display": "15 May 2026 09:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Prelude Therapeutics reported its first-quarter 2026 financial results, highlighting the advancement of PRT12396 into Phase 1 studies for polycythemia vera and myelofibrosis, and plans to file an IND for PRT13722, a KAT6A degrader, by mid-2026. The company appointed Charles Morri", "url": "https://www.globenewswire.com/news-release/2026/05/12/3292693/0/en/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T10:10:03", "published_display": "13 May 2026 10:10", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Reports Q1 2026 Results, Advances Precision Oncology Pipeline and Extends Cash Runway to 2028", "summary": "Prelude Therapeutics announced its Q1 2026 financial results, highlighting significant progress in its precision oncology pipeline, including the initiation of a Phase 1 study for PRT12396 and an upcoming IND filing for PRT13722. The company also reported a major decrease in net ", "url": "https://www.minichart.com.sg/2026/05/12/prelude-therapeutics-reports-q1-2026-results-advances-precision-oncology-pipeline-and-extends-cash-runway-to-2028/", "source_name": "Minichart", "published_at": "2026-05-12T13:09:57", "published_display": "12 May 2026 13:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline Update", "summary": "Prelude Therapeutics has commenced a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis, and plans to file an IND for PRT13722, a KAT6A degrader, by mid-2026. The company reported a reduced net loss of $10.4 million for Q1 2", "url": "https://www.quiverquant.com/news/Prelude+Therapeutics+Initiates+Phase+1+Study+of+PRT12396+and+Provides+R%26D+Pipeline+Update", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T11:14:00", "published_display": "12 May 2026 11:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (NASDAQ: PRLD) trims Q1 2026 loss and extends cash runway to 2028", "summary": "Prelude Therapeutics reported a significantly narrowed net loss of $10.4 million in Q1 2026, benefiting from a substantial reduction in R&D and G&A expenses, while generating $4.58 million in revenue. The company also announced an extended cash runway into the second quarter of 2", "url": "https://www.stocktitan.net/sec-filings/PRLD/8-k-prelude-therapeutics-inc-reports-material-event-41fa58e32dff.html", "source_name": "Stock Titan", "published_at": "2026-05-12T11:10:46", "published_display": "12 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) \u2014 10-Q Summary", "summary": "Prelude Therapeutics Inc. (PRLD) announced its first-quarter 2026 results, reporting revenue of $4.58 million and a net loss of $(0.13) per share, significantly improved from the prior year. This financial improvement was primarily driven by upfront option-related revenue from a ", "url": "https://www.tradingview.com/news/tradingview:5a0299c1a9a3c:0-prelude-therapeutics-inc-1q-2026-revenue-4-58m-eps-0-13-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-12T11:09:57", "published_display": "12 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD", "summary": "Prelude Therapeutics' current cash reserves are projected to fund its operations and capital expenditures into the second quarter of 2028. This extension in cash runway provides the company with over two years to advance its pipeline and strategic initiatives. The announcement in", "url": "https://www.moomoo.com/news/post/69830055/prelude-therapeutics-current-cash-runway-into-2q-2028-prld", "source_name": "Moomoo", "published_at": "2026-05-11T00:10:07", "published_display": "11 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet", "summary": "Shares of Prelude Therapeutics (PRLD) have seen a 17.1% gain recently, and analysts predict a potential upside of 33.6%, with a mean target of $6.88. While price targets alone can be misleading, strong agreement among analysts on upward earnings estimate revisions suggests a legi", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-prelude-135504664.html", "source_name": "Market source", "published_at": "2026-05-08T09:55:00", "published_display": "08 May 2026 09:55", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. Boral Capital Initiates Prelude Therapeutics(PRLD.US) With Buy Rating, Announces Target Price $9", "summary": "D. Boral Capital has initiated coverage on Prelude Therapeutics (PRLD.US) with a Buy rating. The firm has set a target price of $9 for the company's stock. This indicates a positive outlook on Prelude Therapeutics' future performance by D. Boral Capital.", "url": "https://www.moomoo.com/news/post/69341699/d-boral-capital-initiates-prelude-therapeutics-prldus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-05-05T04:09:46", "published_display": "05 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00", "summary": "D. Boral Capital has initiated coverage on Prelude Therapeutics (PRLD) with a \"Buy\" rating and a price target of $9.00, significantly higher than its current trading price of $4.70. Despite a low GF Score of 29/100, indicating challenges in profitability and growth, the company h", "url": "https://www.gurufocus.com/news/8839734/prld-initiates-coverage-on-prelude-therapeutics-price-target-announced-at-900", "source_name": "GuruFocus", "published_at": "2026-05-04T14:54:08", "published_display": "04 May 2026 14:54", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29", "summary": "This article reports that the price target for Prelude Therapeutics (PRLD) has been increased by 19.35%, reaching $6.29. The data implicitly suggests a positive outlook for the company's stock.", "url": "http://www.msn.com/en-us/money/topstocks/prelude-therapeutics-prld-price-target-increased-by-19-35-to-6-29/ar-AA21XGL5?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-04T04:39:05", "published_display": "04 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 87, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview", "summary": "Prelude Therapeutics Inc (PRLD) is projected to report a loss of 24 cents per share. This information comes from an earnings preview provided by Refinitiv. The article is a brief announcement regarding the company's expected financial performance.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41E0M0:0-prelude-therapeutics-inc-expected-to-post-a-loss-of-24-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-05-01T17:39:03", "published_display": "01 May 2026 17:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/prelude-therapeutics-prld-presents-preclinical-092414739.html", "source_name": "Insider Monkey", "published_at": "2026-05-01T09:24:14+00:00", "published_display": "01 May 2026 09:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research", "summary": "Zacks Research has upgraded Prelude Therapeutics (PRLD) to a \"hold\" rating, contributing to a consensus \"Hold\" with an average price target of $7.00. The company recently reported better-than-expected EPS of ($0.20) but missed revenue estimates, posting $5.64 million against a $2", "url": "https://www.marketbeat.com/instant-alerts/prelude-therapeutics-nasdaqprld-rating-increased-to-hold-at-zacks-research-2026-04-30/", "source_name": "MarketBeat", "published_at": "2026-05-01T03:09:46", "published_display": "01 May 2026 03:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Orbimed entities acquire $12.5m in Prelude Therapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPLXp4Tm56eG1OeXRJVEpDY1ZBbm9QOUVJdG9OOVVvSUM3Z2ZDN3NPVTZYWXRCX3NEbWFsMndYblNzOHcybVRqU2Z2RG5Ncm1VU3JkeVV6eGRCUk16MzVjT3VmTkNYbXNFc1ZaalM4WmJwNEhkd0NkS2ZuM09PV05jazAwWnVKNkVvaFFjWmdRX0ItbkdtcW5ZQW1Va2dYTGpMbDRfTFNQMlYwbjJDNlpCNGRRZVVYZG80OVg5TE16LTJkQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQejF4eFNGVHZzMnNzQnBGYWNHX3JuZU5kWU1QSEdfN1cyWDRCdE9yWFJuTGxhSE9UOE9NOW9jQzU5YWUtRlBfdGxtSWpCbFNVX3BEWkVzODdlR0xHX21KVklubi1Ubk1tcmFMemFCZ0QzM043ZXoxNGlDUmpyVV9EUG5wQ3p6QWxjbEtfVkRkWGgxbkJqWWFiUFhrdWx5QVZUWjhPX0tya2JvQldLYTVHOWZUTHBWUHk4NDUwVE0wd1cyMTQwLUw5dlVZQndVaXFJeUNwZk93?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Prelude Therapeutics Prices $90 Million Underwritten Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/prelude-therapeutics-prices-90-million-110959029.html", "source_name": "MT Newswires", "published_at": "2026-04-20T11:09:59+00:00", "published_display": "20 Apr 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/prelude-therapeutics-presents-preclinical-data-100000808.html", "source_name": "GlobeNewswire", "published_at": "2026-04-20T10:00:00+00:00", "published_display": "20 Apr 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNZkZ1N3FqYlFBdEJNcV95ZG0xR0hFRXV0dXJuOERfU3BNQ0pCb04tWXg2N0h4TEtSUnJ3LWIzdDE4V1k3QnUzQWRHaV9CNlgwd0s3S2V2SWdzOWdMSDlUMDBRLV9fbWFyU3Zma1ZIWkdidWJsUWFrQ25kbkcxdnV5cXhfUGVGLXpyNlFJR29hcGxCdl93eXgteC1IUkhSOFZ5dkhnRU93ejFwMkpabWJXc2hqN21WOVhfRm1sTjJQWXFjSVljZ0txRFpMWnJWSmwwaEVUVkV1MVBMMkNFZWxJRXJ3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Prelude Therapeutics Incorporated's (NASDAQ:PRLD) biggest owners are retail investors who got richer after stock soared 12% last week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Prelude Therapeutics (PRLD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1VdVZVQnJEdnBsNHF1VndkUUFsMEVjRVVNRjcyLWh4RlR2dGFXWWgzVWVGanZ6aHY3MmRkSEh2R3FNSk0xZ01OU2FzNkZ6SXFvRnVHTlV0ODhKOVJtcERkNU9idXItTkE0Ylo3Wg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude (NASDAQ: PRLD) signs Incyte option for JAK2V617F; $60M and pipeline refocus", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOekM4Sl9jSmJNQ3lWYm51R0wxMEt5d015a0pjeGJ1TnVwN0xlWXNkQ0JCQXdlQ3BTQUFSWlFCdUg0Y213ZjhqeFd3THMxUUhSbE9Sc1h3ZURycHBYMnZ1b2FOVTN1a2VFeDY5SDR0ZDR3YWFGWGpURUNtbWI2TXU3VER2Zm9Sd1V0c212WGxEUExtUXNvbUhabnpleUVOR1RWTFpUUlh1OA?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPeXpnVFFQU0tmdG5leU1UN2tiWXlwS2pLbzZBLV9NSjhwblo2ZEgtQlJma1Z6eUNFSUhHRWxRTGdaMWMzb2pIYzY4Nnd6bm5PNnF5dkVId19KX1pDbWxZTUZValBBRFJyOTRvZnA5NXAxbmJrUEFuRTBQUU1ILVJSRWliV1ZKSzhiSTJyX0J5N1BfdWpMVlhic3h3TWhUMS00aVB0ZjJldlFySlVvbURNTDlKZTJXQ1drWmJQY1hXVEQxOE9Q?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-15T12:32:44+00:00", "published_display": "15 Jul 2026 12:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Declines 7.6% as Key Support Level Comes into Play - High Reward Trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPSFduZE1NTDFfOTFvVUlfc01IaWFBR3p1LXJ6ZkNjRGtVbVc0Q25JTm1jME9PdTU5UXpYODhyd01wVXFwQnBETHNvc1lhOThxemlfc2VEeUQ1UHBTb0ZzWGQxWDNSMmZIYkdzeTRWT1ZON05zSEtzeXl4ektyWU5ZLUstWkRtcUhJREtndGVFc3BJQUpGVzg3NnRfYVVVOFRGcndBQlVDeHFsaXBBV2xaRWdPaw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-14T01:36:17+00:00", "published_display": "14 Jul 2026 01:36", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Q1 2026 Earnings: EPS Beat by 48.7% but Stock Slides 7.6% on Pre-Revenue Status - Profit Growth Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQYVZqdE5hS3Y3TFQzaE16TkpILWlTQndhTm9FOFY2eF9rbkNhV2ZMc3J4TmNaSTVHR3JFSTRBNmNfel92cXB4Rkl0RHVTXzE2ZXNyb1ppNm9ocmt0RVQyYm9falZCVkhVb0lnWDVNbHdrcEtkZ0NVTWpyZmZJWUFZQ0d2NERPUGpsUDRyeHhXNTUxVV9YaUdodXR0N0dqWXVkVWRSVTIxcm1aQ24zWFJORy0zTUVpeklNSWdKM0xsYW0wbFlrVjgwUHdkTWtBLTB2?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-13T20:42:33+00:00", "published_display": "13 Jul 2026 20:42", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Prelude Therapeutics stock rating on IND filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOQTl5U1ZvU1BBazJuUnJSd2JTVG1SWkIwS2NEX2pGY3BOR3dTY1ZSWUJBSzVkWEpITk9BWG5KWUUzQXg4a2hGUFFTWmFJazkteXNsNTk4YldMeHlHc2xWWEJyT0dYNXZXWlNWdEhwbF9Idl9XdFl4ZndlOGhPdV9KNV96eFQxYUZoY0pEN2QyRU4xNEljeExjN0NESWNJQmFxeEZGT1ZhaEx4Y0RCSVhNUDNHX0ZIZGN3YXJHd1RvZXpTeTdhTWc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) Surges 7.4%: Breakout or Bounce? - FRAMA Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPSVpYRHd4MHJjUXNsRG1MQ0R1VUdVUGNiWkxQTk9nM3dkZ05lWnBwOWVyaks2UktnVGtNMjFHNzdLVEVrazROQm9JYXZULUNLYUNhNEU1eUYtLWVOM05hSUxsVkJDODFncUZqa3owVVp0eTFWQjdzVzFWYUp2bWV1TVBfb0J2NmdZMUZZVGxZU2toLVBCQnYtRDduVzJtMzA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2500 Growth Benchmark", "summary": "Prelude Therapeutics Incorporated (NasdaqGS:PRLD) has been added to the Russell 2500 Growth Benchmark. This news coincides with several other Russell index additions for Prelude Therapeutics on the same day, including the Russell Small Cap Comp Growth Benchmark, Russell 2000 Inde", "url": "https://www.marketscreener.com/news/prelude-therapeutics-incorporated-nasdaqgs-prld-added-to-russell-2500-growth-benchmark-ce7f5fdfdd89f423", "source_name": "marketscreener.com", "published_at": "2026-06-29T20:09:48", "published_display": "29 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 2500 Index", "summary": "Prelude Therapeutics Incorporated (NasdaqGS:PRLD) has been added to the Russell 2500 Index. This inclusion is part of a broader set of additions to various Russell indices, including the Russell Small Cap Comp Growth Benchmark, Russell 2500 Growth Benchmark, Russell 2000 Index, R", "url": "https://www.marketscreener.com/news/prelude-therapeutics-incorporated-nasdaqgs-prld-added-to-russell-2500-index-ce7f5fdfd18bf525", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:41:26", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Microcap Growth Benchmark Index", "summary": "Prelude Therapeutics Incorporated (NasdaqGS:PRLD) has been added to the Russell Microcap Growth Benchmark Index. The company is a precision oncology firm focused on developing novel cancer medicines, with a pipeline including kinases, targeted protein degraders, and degrader anti", "url": "https://www.marketscreener.com/news/prelude-therapeutics-incorporated-nasdaqgs-prld-added-to-russell-microcap-growth-benchmark-index-ce7f5fded089ff27", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:16:00", "published_display": "29 Jun 2026 08:16", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNU0o0QVFQVTdFRmJZVlU3TEF0YkpEVGxGYTNzSWVjUl9jSW9nRzYtWGR3X1owNXBWUmdaVXBmRkI1U2pFa1gwTEJZMDdrLTdMUE9RcmNUZjNVaFVka0tkZGpDajlHbTV5RE1OX3ZUZDA0ZGlnbHpLSGlYSzNCMng0ZTAtaDBBczRnaS1uU0hEdWZTZmpvZkQ0b0lVLVlfWlhWaVJlSWZmb2ppaS1xWlpBdHY3WW8xNTNhYS00ODJZUzJidXN1alY2d1FVOVUtSUlUUXRvSUVn?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2000 Dynamic Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxORW5CdlJRWW5IUzZ2NURGekg0WmtwZmlJTTlmeUpnTmZ2Qlhqb3loUE96bDNUaDk5VFBaeEw3Z0ZlcFpuVHgweGRxTS1sSUFDR0U2ejZBU1pocnZiSHI4X1NkSE1ZUzUweVg0b3hEQUgyalQ0S2lhTVQ5MmthZzVYa2hXM1NBQXlFUmc3Y2h2YXRUdldWUlY4Y2FMMjFiNUNlRS1oVDZocE1aZ0hYaUxSNWdTRndLc0VwT1RLeF82QXZlbDNTdl9tbU92aExsN0pSY0E?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 3000 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNbXVBMnR5UHY0U05JZVNkN0F6cHZhSkdlTlpETVdlZnpPNjE1eV9pYXFoMlF3amgtNl9lakM1UlBTWkNnV2FmeUdhSF9oNXRzdXJFV1l4M0NSeFZqeEZpTVRUeWFlRHItZDdJU2c1WXBVSWJmaHBNRFdwUTd4TkZra250Rm12Ymt5YUFYRFN6WmlrNmdZRXdzZEZNdDd2ZEQzMTRFcEhjX0NkcnI0bHZOOV82WGhNaFdNTGdFTHlibWhPSXpQbUJj?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Completeness Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOckNNR1p1c0dfdy1OdXdEaC1rUjlNNkM3VlVaNXRfVDBZd0VmT05hNHcyMjBvQ0RXSzZEQ1NWRFduczM3YTJva2dnUHJhYnlPZFFXUHUwampMaklYTlFEOGI4ekhXNGVuWWQ5NXk4Mlh0UmZhYjNQaDljdVNXQmFHSE92bXpJXzRoYXVqaXJ3UzNOTm9QUDhjTy1vY0dmbkVUOU5hMTEwc1JnbUFWeGFxSlZkWHZ0S0FSQlhCNGhNVld1T1JYbkgxN0d1ODE5QV82MG1aMm13QjlsaDI4RGxF?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) Slips Slightly as Traders Eye Key Support Zone - Triangle Correction", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQeTdnQjd1elk4d1dTRE5fdVBSRVg5X3pSU0liTjNtcUM1Rk42cTRzTkRBUFVfZXV2M2NRZGQ1LS0zdDYzcjhaajQtNjZPdnFTc1JVcGI5d3dCNVBaQ2lZSkVWalQ5eXQtUjZIQ052RkVmNUwtS3dEdElmVjU3OHpnWFJETkgxT05yMFhaMEpQVGJfV05jSDhIR2Y0X3ZPMHBvSW9xbW1PaHdNZV9vS1ZTbzVMWnp3LUE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Valuation: PE, PB & Fair Value Analysis", "summary": "This article analyzes the valuation of Prelude Therapeutics Inc (PRLD), highlighting its current valuation score of 6.01, which ranks it 367 out of 389 in the Biotechnology & Medical Research industry. It notes the company's current P/E ratio of -4.34, which is significantly belo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T12:09:50", "published_display": "18 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Prelude Therapeutics Inc (PRLD), detailing its current stock price momentum, support and resistance levels, and indicator and moving average readings as of June 18, 2026. The stock is currently trading between $3.58 and $4.87, with va", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/technical", "source_name": "TradingKey", "published_at": "2026-06-17T23:39:15", "published_display": "17 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Prelude Therapeutics Inc (PRLD), including its major individual and institutional investors. Key shareholders like OrbiMed Advisors, Baker Bros. Advisors LP, and RA Capital Management LP are highlighted, along with a breakdown of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T21:57:40", "published_display": "17 Jun 2026 21:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article for Prelude Therapeutics Inc (PRLD) states that relevant data regarding the company's revenue breakdown by business segment and by region have not yet been disclosed. It indicates that the company's financial information in these specific categories is currently unav", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:37", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Market Sentiment Around Loss-Making Prelude Therapeutics Incorporated (NASDAQ:PRLD)", "summary": "This article examines the market sentiment surrounding Prelude Therapeutics (NASDAQ:PRLD), a loss-making biotechnology company. It highlights that despite recent positive movements in its stock price, analysts have maintained a bearish stance with an average price target indicati", "url": "https://www.moomoo.com/news/post/71485537/market-sentiment-around-loss-making-prelude-therapeutics-incorporated-nasdaq-prld", "source_name": "Moomoo", "published_at": "2026-06-17T13:11:00", "published_display": "17 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc (PRLD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Prelude Therapeutics Inc (PRLD) has an earnings forecast score of 8.67, ranking it 71st in the Biotechnology & Medical Research industry. Analysts project an average price target of $4.00, with an upside potential of 79.37%. Most analysts currently rate PRLD as a \"Buy.\"", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-prld/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T23:09:29", "published_display": "16 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) shareholders back directors, auditor and say-on-pay", "summary": "Prelude Therapeutics shareholders approved all proposals at their 2026 Annual Meeting. They re-elected three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratified Ernst & Young LLP as the independent auditor for 2026, and gave advisory approval for 2025 e", "url": "https://www.stocktitan.net/sec-filings/PRLD/8-k-prelude-therapeutics-inc-reports-material-event-aed5b467638c.html", "source_name": "Stock Titan", "published_at": "2026-06-11T10:40:37", "published_display": "11 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) director receives 38,000 stock options at $3.94 strike", "summary": "Prelude Therapeutics director Paul A. Friedman was granted 38,000 stock options at an exercise price of $3.94 per share, expiring on June 8, 2036. These options are part of his board compensation and will vest on the earlier of the company\u2019s next annual stockholder meeting or one", "url": "https://www.stocktitan.net/sec-filings/PRLD/form-4-prelude-therapeutics-inc-insider-trading-activity-653de6cd6079.html", "source_name": "Stock Titan", "published_at": "2026-06-11T09:10:22", "published_display": "11 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options", "summary": "Prelude Therapeutics Inc. director Katina Dorton was granted 38,000 stock options with an exercise price of $3.94 per share, expiring on June 8, 2036. The options will fully vest on the earlier of the next annual stockholder meeting or the one-year anniversary of the grant date, ", "url": "https://www.stocktitan.net/sec-filings/PRLD/form-4-prelude-therapeutics-inc-insider-trading-activity-78d73cac888a.html", "source_name": "Stock Titan", "published_at": "2026-06-10T22:09:51", "published_display": "10 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Prelude Therapeutics Inc Insider Trading Activity", "summary": "Prelude Therapeutics Inc. director David P. Bonita was granted 38,000 stock options with an exercise price of $3.94 per share, expiring on June 8, 2036. The options will vest upon the company's next annual stockholder meeting or the one-year anniversary of the grant date, conting", "url": "https://www.stocktitan.net/sec-filings/PRLD/form-4-prelude-therapeutics-inc-insider-trading-activity-24bb5f4378d1.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:09:24", "published_display": "10 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) director granted 38,000 stock options at $3.94", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOY1k2dlFYQlEtaXdxenM1Y2ZQb0lZUGRDb2ZNUl91elNmUjc1b0VSTHE1Y0p4T0xhdld0RjIweTMzSHNwWEd2bWFBQjFfNkJyc1R6eUx2dFJNc3NhMjR6dXBUM1VsaXlGekNaWXdUYUM1VlJrZExwa1JfWk5idHFKMno5VFdiUkg2U1AxbWs0NHIyUUlOUUtyZFQyZzFkMjFYYzJIY3VFVnh4Y2dpQWxTYWw1aXlSV0dTQlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRLD: All director, auditor, and executive compensation proposals were approved by shareholder vote", "summary": "Shareholders of Prelude Therapeutics Incorporated (PRLD) approved all proposals at their recent annual general meeting. This included the election of three directors, ratification of the company's auditor, and approval of executive compensation and its annual review. The final re", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3531294:0-prld-all-director-auditor-and-executive-compensation-proposals-were-approved-by-shareholder-vote/", "source_name": "TradingView", "published_at": "2026-06-09T13:10:11", "published_display": "09 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNc0k4enlKM1dzYWZFQlF0eUN0QnlhVFBLbHlaSUx6QjhFUkE2NWxRaU0yOHIzTXFaeFYtSi1qaVlnSXJkY3ExWE8yUG1FWHowcTROUDJsZFNkNkhWdjNSN2E5RVBOdHVhTEpWQ1E5WUxfb2ZlVXhSYWFTMlNpb3FIaEJvQ29mTEVXNG9mdWZnWDJwMm1ydDltV0xtYmc1S1JKcVB4bUpkZHZDQzRVWEE?oc=5", "source_name": "Market source", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRLD - Prelude Therapeutics Inc Stock Price and Quote", "summary": "This page provides detailed stock information for Prelude Therapeutics Inc (PRLD), including its current stock price, financial metrics, analyst ratings history, and recent news. It lists key financial data, performance indicators, insider transactions, and a chronological news f", "url": "https://finviz.com/stock?t=PRLD", "source_name": "Finviz", "published_at": "2026-05-29T15:41:33", "published_display": "29 May 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (Nasdaq:PRLD) - Stock Analysis", "summary": "This extensive analysis of Prelude Therapeutics (PRLD) covers its stock performance, financial health, and pipeline developments. The company, a clinical-stage precision oncology firm, is currently unprofitable but forecasts strong revenue growth. Recent updates include positive ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prld/prelude-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-05-20T11:12:46", "published_display": "20 May 2026 11:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates", "summary": "Following its first-quarter results, Prelude Therapeutics (NASDAQ:PRLD) saw a dip in share price, but analysts quickly upgraded their estimates. Revenue forecasts for 2026 increased to US$27.3m, and the projected loss per share significantly narrowed to US$0.37. The company's pri", "url": "https://www.sahmcapital.com/news/content/prelude-therapeutics-incorporated-nasdaqprld-reported-earnings-last-week-and-analysts-are-already-upgrading-their-estimates-2026-05-16", "source_name": "Sahm", "published_at": "2026-05-17T10:40:45", "published_display": "17 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNkRnMTVndWlSUmxTZWh2YV9Gb3pfbFB4amluWkVtR3BkTzRWRWlNcjZXU2FZY3JtWlowMUd4M3hYaGZmZG1Xa19qVjJwdHI3QzRoclNWUW5KTDFGa2hicVprTmVGYnotTzVObTBaUUo0ZnBZWHIwZDctT09jbmxmNWo2bkdJMVFQOTZNa0NSZW04cHhySWRBNW0xdVplM2VNMVhzeF9mTFZkWmxNSlllY1J3?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech", "summary": "Goldman Sachs has initiated coverage of Prelude Therapeutics Inc. (NASDAQ:PRLD) with an \"Early-Stage Biotech\" rating. The clinical-stage company, which develops cancer medicines, has seen its stock gain 377% over the past year and possesses over $10 billion in potential unadjuste", "url": "https://www.investing.com/news/analyst-ratings/goldman-sachs-initiates-prelude-therapeutics-stock-coverage-as-earlystage-biotech-93CH-4691443", "source_name": "Investing.com", "published_at": "2026-05-15T09:40:27", "published_display": "15 May 2026 09:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Prelude Therapeutics reported its first-quarter 2026 financial results, highlighting the advancement of PRT12396 into Phase 1 studies for polycythemia vera and myelofibrosis, and plans to file an IND for PRT13722, a KAT6A degrader, by mid-2026. The company appointed Charles Morri", "url": "https://www.globenewswire.com/news-release/2026/05/12/3292693/0/en/prelude-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T10:10:03", "published_display": "13 May 2026 10:10", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Reports Q1 2026 Results, Advances Precision Oncology Pipeline and Extends Cash Runway to 2028", "summary": "Prelude Therapeutics announced its Q1 2026 financial results, highlighting significant progress in its precision oncology pipeline, including the initiation of a Phase 1 study for PRT12396 and an upcoming IND filing for PRT13722. The company also reported a major decrease in net ", "url": "https://www.minichart.com.sg/2026/05/12/prelude-therapeutics-reports-q1-2026-results-advances-precision-oncology-pipeline-and-extends-cash-runway-to-2028/", "source_name": "Minichart", "published_at": "2026-05-12T13:09:57", "published_display": "12 May 2026 13:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline Update", "summary": "Prelude Therapeutics has commenced a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis, and plans to file an IND for PRT13722, a KAT6A degrader, by mid-2026. The company reported a reduced net loss of $10.4 million for Q1 2", "url": "https://www.quiverquant.com/news/Prelude+Therapeutics+Initiates+Phase+1+Study+of+PRT12396+and+Provides+R%26D+Pipeline+Update", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T11:14:00", "published_display": "12 May 2026 11:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (NASDAQ: PRLD) trims Q1 2026 loss and extends cash runway to 2028", "summary": "Prelude Therapeutics reported a significantly narrowed net loss of $10.4 million in Q1 2026, benefiting from a substantial reduction in R&D and G&A expenses, while generating $4.58 million in revenue. The company also announced an extended cash runway into the second quarter of 2", "url": "https://www.stocktitan.net/sec-filings/PRLD/8-k-prelude-therapeutics-inc-reports-material-event-41fa58e32dff.html", "source_name": "Stock Titan", "published_at": "2026-05-12T11:10:46", "published_display": "12 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) \u2014 10-Q Summary", "summary": "Prelude Therapeutics Inc. (PRLD) announced its first-quarter 2026 results, reporting revenue of $4.58 million and a net loss of $(0.13) per share, significantly improved from the prior year. This financial improvement was primarily driven by upfront option-related revenue from a ", "url": "https://www.tradingview.com/news/tradingview:5a0299c1a9a3c:0-prelude-therapeutics-inc-1q-2026-revenue-4-58m-eps-0-13-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-12T11:09:57", "published_display": "12 May 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD", "summary": "Prelude Therapeutics' current cash reserves are projected to fund its operations and capital expenditures into the second quarter of 2028. This extension in cash runway provides the company with over two years to advance its pipeline and strategic initiatives. The announcement in", "url": "https://www.moomoo.com/news/post/69830055/prelude-therapeutics-current-cash-runway-into-2q-2028-prld", "source_name": "Moomoo", "published_at": "2026-05-11T00:10:07", "published_display": "11 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet", "summary": "Shares of Prelude Therapeutics (PRLD) have seen a 17.1% gain recently, and analysts predict a potential upside of 33.6%, with a mean target of $6.88. While price targets alone can be misleading, strong agreement among analysts on upward earnings estimate revisions suggests a legi", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-prelude-135504664.html", "source_name": "Market source", "published_at": "2026-05-08T09:55:00", "published_display": "08 May 2026 09:55", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. Boral Capital Initiates Prelude Therapeutics(PRLD.US) With Buy Rating, Announces Target Price $9", "summary": "D. Boral Capital has initiated coverage on Prelude Therapeutics (PRLD.US) with a Buy rating. The firm has set a target price of $9 for the company's stock. This indicates a positive outlook on Prelude Therapeutics' future performance by D. Boral Capital.", "url": "https://www.moomoo.com/news/post/69341699/d-boral-capital-initiates-prelude-therapeutics-prldus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-05-05T04:09:46", "published_display": "05 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00", "summary": "D. Boral Capital has initiated coverage on Prelude Therapeutics (PRLD) with a \"Buy\" rating and a price target of $9.00, significantly higher than its current trading price of $4.70. Despite a low GF Score of 29/100, indicating challenges in profitability and growth, the company h", "url": "https://www.gurufocus.com/news/8839734/prld-initiates-coverage-on-prelude-therapeutics-price-target-announced-at-900", "source_name": "GuruFocus", "published_at": "2026-05-04T14:54:08", "published_display": "04 May 2026 14:54", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29", "summary": "This article reports that the price target for Prelude Therapeutics (PRLD) has been increased by 19.35%, reaching $6.29. The data implicitly suggests a positive outlook for the company's stock.", "url": "http://www.msn.com/en-us/money/topstocks/prelude-therapeutics-prld-price-target-increased-by-19-35-to-6-29/ar-AA21XGL5?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-04T04:39:05", "published_display": "04 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 87, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview", "summary": "Prelude Therapeutics Inc (PRLD) is projected to report a loss of 24 cents per share. This information comes from an earnings preview provided by Refinitiv. The article is a brief announcement regarding the company's expected financial performance.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41E0M0:0-prelude-therapeutics-inc-expected-to-post-a-loss-of-24-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-05-01T17:39:03", "published_display": "01 May 2026 17:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/prelude-therapeutics-prld-presents-preclinical-092414739.html", "source_name": "Insider Monkey", "published_at": "2026-05-01T09:24:14+00:00", "published_display": "01 May 2026 09:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research", "summary": "Zacks Research has upgraded Prelude Therapeutics (PRLD) to a \"hold\" rating, contributing to a consensus \"Hold\" with an average price target of $7.00. The company recently reported better-than-expected EPS of ($0.20) but missed revenue estimates, posting $5.64 million against a $2", "url": "https://www.marketbeat.com/instant-alerts/prelude-therapeutics-nasdaqprld-rating-increased-to-hold-at-zacks-research-2026-04-30/", "source_name": "MarketBeat", "published_at": "2026-05-01T03:09:46", "published_display": "01 May 2026 03:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Orbimed entities acquire $12.5m in Prelude Therapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPLXp4Tm56eG1OeXRJVEpDY1ZBbm9QOUVJdG9OOVVvSUM3Z2ZDN3NPVTZYWXRCX3NEbWFsMndYblNzOHcybVRqU2Z2RG5Ncm1VU3JkeVV6eGRCUk16MzVjT3VmTkNYbXNFc1ZaalM4WmJwNEhkd0NkS2ZuM09PV05jazAwWnVKNkVvaFFjWmdRX0ItbkdtcW5ZQW1Va2dYTGpMbDRfTFNQMlYwbjJDNlpCNGRRZVVYZG80OVg5TE16LTJkQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQejF4eFNGVHZzMnNzQnBGYWNHX3JuZU5kWU1QSEdfN1cyWDRCdE9yWFJuTGxhSE9UOE9NOW9jQzU5YWUtRlBfdGxtSWpCbFNVX3BEWkVzODdlR0xHX21KVklubi1Ubk1tcmFMemFCZ0QzM043ZXoxNGlDUmpyVV9EUG5wQ3p6QWxjbEtfVkRkWGgxbkJqWWFiUFhrdWx5QVZUWjhPX0tya2JvQldLYTVHOWZUTHBWUHk4NDUwVE0wd1cyMTQwLUw5dlVZQndVaXFJeUNwZk93?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Prices $90 Million Underwritten Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/prelude-therapeutics-prices-90-million-110959029.html", "source_name": "MT Newswires", "published_at": "2026-04-20T11:09:59+00:00", "published_display": "20 Apr 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/prelude-therapeutics-presents-preclinical-data-100000808.html", "source_name": "GlobeNewswire", "published_at": "2026-04-20T10:00:00+00:00", "published_display": "20 Apr 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNZkZ1N3FqYlFBdEJNcV95ZG0xR0hFRXV0dXJuOERfU3BNQ0pCb04tWXg2N0h4TEtSUnJ3LWIzdDE4V1k3QnUzQWRHaV9CNlgwd0s3S2V2SWdzOWdMSDlUMDBRLV9fbWFyU3Zma1ZIWkdidWJsUWFrQ25kbkcxdnV5cXhfUGVGLXpyNlFJR29hcGxCdl93eXgteC1IUkhSOFZ5dkhnRU93ejFwMkpabWJXc2hqN21WOVhfRm1sTjJQWXFjSVljZ0txRFpMWnJWSmwwaEVUVkV1MVBMMkNFZWxJRXJ3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude Therapeutics Incorporated's (NASDAQ:PRLD) biggest owners are retail investors who got richer after stock soared 12% last week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Prelude Therapeutics (PRLD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1VdVZVQnJEdnBsNHF1VndkUUFsMEVjRVVNRjcyLWh4RlR2dGFXWWgzVWVGanZ6aHY3MmRkSEh2R3FNSk0xZ01OU2FzNkZ6SXFvRnVHTlV0ODhKOVJtcERkNU9idXItTkE0Ylo3Wg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prelude (NASDAQ: PRLD) signs Incyte option for JAK2V617F; $60M and pipeline refocus", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOekM4Sl9jSmJNQ3lWYm51R0wxMEt5d015a0pjeGJ1TnVwN0xlWXNkQ0JCQXdlQ3BTQUFSWlFCdUg0Y213ZjhqeFd3THMxUUhSbE9Sc1h3ZURycHBYMnZ1b2FOVTN1a2VFeDY5SDR0ZDR3YWFGWGpURUNtbWI2TXU3VER2Zm9Sd1V0c212WGxEUExtUXNvbUhabnpleUVOR1RWTFpUUlh1OA?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 65, "sentiment_summary": {"positive": 26, "negative": 4, "neutral": 35, "score": 59, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.95, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 11.0, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 26, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 4.8, "latest_week": "2026-07-10", "one_week_move": -2.1, "four_week_move": 7.0, "twelve_week_move": 8.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.000276, "market_dynamics_buy_signal": false, "relative_strength": 67.754581, "fair_value_gap": 79.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.7341, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.1% over one week, +7.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "marketscreener.com", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "TradingKey", "count": 5}, {"label": "dars.gov.et", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Moomoo", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 57}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "57", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.1% over one week, +7.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com"}], "updated_at": "2026-07-16T00:50:06.124828+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}